Generate Biomedicines reports Q2 2026 results, advances asthma and oncology pipeline
Phase 3 asthma trials expand recruitment and an oncology combination study completes enrollment as cash falls to $457.4 million.
Generate Biomedicines reported second quarter 2026 results on August 6, 2026, highlighting progress across its respiratory and oncology programs. The company's global SOLAIRIA-1 and SOLAIRIA-2 Phase 3 studies of GB-0895 in severe asthma have received regulatory approvals in 33 of a planned 42 countries, with recruitment underway across all six global regions the company is targeting.1
At the European Respiratory Society Congress 2026, Generate plans to present safety, pharmacokinetic, and pharmacodynamic data from its ongoing Phase 1b study of GB-0895 in adults with COPD on September 81, along with two additional posters covering asthma data and Phase 3 trial design.
In oncology, the company said every patient in the first cohort of its Phase 1 study of GB-4362 alongside enfortumab vedotin and pembrolizumab for locally advanced or metastatic urothelial cancer has been enrolled, with initial dosing underway.1 The FDA has granted GB-4362 Fast Track status, a designation the company says applies to preventing or reducing toxicity linked to enfortumab vedotin in urothelial cancer patients.1 A trial-in-progress abstract on GB-4362 is set for poster presentation at the ESMO Congress 2026 in Madrid, held October 23 to 27.
Separately, Novartis advanced a biologic engineered on Generate's platform into its preclinical pipeline through a multi-target collaboration, which the company said marks the first time an AI-designed biologic has reached that stage.1 A Roswell Park collaboration testing GB-5267, an IL-18 armored CAR T therapy for platinum-resistant ovarian cancer, has also begun recruiting, with the first patient expected to be dosed in 2026.1
On finances, the company reported cash, cash equivalents, and marketable securities of $457.4 million as of June 30, 2026, down from $516.6 million at the end of the first quarter.1 Generate said it expects this to fund operations into the first half of 2028, while acknowledging it will need additional capital for long-term operations.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.